SARS CoV2 in older patients with Parkinson’s.
Objective: To review the clinical presentation and management of SARS-CoV 2 in older patients with Parkinson’s during the first wave of the pandemic in West…INTERLEUKIN 4 (IL-4),INTERLEUKIN 1α (IL-1α) AND CORTISOL SERUM LEVELS IN PARKINSON’S DISEASE PATIENTS UNDERGOING DANCE THERAPY
Objective: To identify changes in anti and pro-inflammatory cytokines and cortisol hormone levels in patients with Parkinson's disease undergoing dance therapy. Background: Parkinson’s disease(PD) pathophysiology…Clinical Outcomes in Parkinson’s with COVID 19 during the’ first wave’ in West Berkshire, United Kingdom (UK)
Objective: To review the outcomes of COVID 19 during the first wave in patients with Parkinson’s in West Berkshire, UK. Background: UK is one of…Post-Covid-19 Parkinson’s disease: a Brazilian case series.
Objective: To describe two patients with post-COVID-19 Parkinson’s disease (PD) and discuss their possible causes. Background: PD is a neurodegenerative disorder characterized by motor and…Ultrastructural Characterization of Monocytes in Parkinson’s Disease and GBA mutations
Objective: To identify morphological changes in circulating CD14+ monocytes in manifesting and non-manifesting carriers of mutations of the GBA gene and Parkinson’s disease (PD). Background: Mutations of…Mutations in GBA and LRRK2 are not associated with increased inflammatory markers
Objective: To assess central and peripheral cytokines among Parkinson's disease (PD) patients with mutations in the LRRK2 and GBA genes as well as among non-manifesting…Integrated Multi-omics of the Gut Microbiome Reveal 2-Hydroxypyridine as a Novel Molecule Relevant to Parkinson’s Disease Pathogenesis
Objective: To search for molecular links between Parkinson’s disease (PD) pathogenesis and gut microbes based on integrated multi-omic analyses of fecal samples from patients with…Targeted plasmaproteome identifies a distinct biomarker panel in early and prodromal Parkinson’s disease
Objective: To identify protein biomarkers in plasma of patients with Parkinson’s disease (PD). Background: Inflammation plays a key role in the initiation and progression of…The gut microbiome in Parkinson’s disease: longitudinal insights into disease progression and the use of device-assisted therapies.
Objective: We investigated the temporal stability of gut microbiome (GM) profiles from Parkinson’s disease (PD) patients initiating device-assisted therapies (DAT) and in a separate cohort…Gut microbiota and nutritional profiles of Parkinson’s disease patients.
Objective: We investigated the gut microbiome (GM) composition in association with various clinical features and nutritional data in a large cross-sectional Australian Parkinson’s disease (PD)…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 22
- Next Page »